Anadys Pharmaceuticals, Inc.
http://www.anadyspharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Anadys Pharmaceuticals, Inc.
Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’
Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline.
Abecma Or Bust: 2seventy Sells Final Research Program To Novo
2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.
Finance Watch: More Than $2.5bn In New VC Funding, Capital For Pharma Manufacturing In Africa
Private Company Edition: J.P. Morgan raised more than $500m in its first venture fund and the Africa Health Security Investment Plan gained $2bn. Also, Marea launched with $190m, Iambic’s series B expanded to $150m, InduPro raised an $85m series A and Elion closed an $81m series B.
Naloxone Firms Commit To Boost Capacities In White House Opioid Overdose Epidemic Meeting
Emergent BioSolutions, Harm Reduction Therapetuics, Hikma, Teva and other drug manufacturers commit to increased supply of naloxone and nalmefene in meeting with ]White House Office of National Drug Control.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice